GlassScriptPhysician profile
Darryl A Stern
NPI 1104811223
$12,733.63
in general payments reported to CMS, 2019-2025
61 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $1,277 · 2021: $1,912 · 2022: $2,398 · 2023: $2,053 · 2024: $1,764 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,926.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,812.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,330.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,192.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,102.37 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Pfizer INC. | $822.35 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $718.58 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.91 | 2020-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $446.68 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $417.31 | 2019-2023 | Trintellix |
| Amgen INC. | $378.15 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Novartis Pharmaceuticals Corporation | $368.40 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.62 | 2022-2025 | |
| Exact Sciences Corporation | $272.92 | 2023-2025 | Cologuard Collection Kit |
| Preventric Diagnostics, INC. | $260.20 | 2022 | |
| Merck Sharp & Dohme LLC | $217.50 | 2020-2024 | Dificid |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.